Data as of Oct 17
| +0.25 / +0.93%|
The 6 analysts offering 12-month price forecasts for Epizyme Inc have a median target of 42.50, with a high estimate of 52.00 and a low estimate of 35.00. The median estimate represents a +56.77% increase from the last price of 27.11.
The current consensus among 7 polled investment analysts is to Buy stock in Epizyme Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.